Search
News & Events
Warburton Community book launchThe Kids Research Institute Australia Founding Director Professor Fiona Stanley will help launch a series of children's books on Monday, written by local Aboriginal people
News & Events
Folate researcher awarded for work to prevent birth defectsProfessor Carol Bower has received the prestigious ICBDSR Distinguished Service Award for her work on birth defects - a career that spans 35 years.
News & Events
Funding boost to help researchers better understand how language developsTelethon Kids Institute researchers have been awarded an Australian Research Council grant to explore how testosterone levels in the womb can impact on a child'
News & Events
New collaboration to boost kids early childhood development outcomes across AustraliaA new collaboration has been launched to fast track research into action to improve outcomes in the crucial early years of child development and learning.
News & Events
New research into Vitamin D and Sunlight has created Project D-LightProject D-Light aims to understand and harness the benefits of vitamin D and sunlight for Australian children while protecting them from excess UV.
News & Events
Re-think on strategies to prevent whooping cough in newbornsGovernments should rethink strategies to prevent whooping cough in newborn infants, including booster vaccination of close contacts of the baby.
Research
InfluenzaInfluenza (commonly known as the flu) is caused by a highly contagious virus spread mainly through coughing and sneezing. An annual flu vaccination is the most effective way to prevent flu outbreaks.
Research
Novel GABAAR antagonists target networked gene hubs at the leading-edge in high-grade gliomasIon channel activity underlying biological processes that drive high-grade gliomas (HGG) is largely unknown. We aimed to determine the networking of ion channel genes and validate their expression within HGG patient tumors, to identify ion channel-targeting drugs that would inhibit tumor-promoting processes.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Research
Can Respiratory Hospital Admissions in Children with Cerebral Palsy Be Reduced? A Feasibility Randomized Controlled Trial (RESP-ACT)To investigate the feasibility of implementing recommendations of the consensus statement for the Prevention and Management of Respiratory Disease in children with severe cerebral palsy (CP) via RESPiratory hospital Admissions in children with cerebral palsy: a feasibility randomized Controlled Trial (RESP-ACT).